Avanos Medical (AVNS) Expected to Announce Earnings on Tuesday

Key Points

• Avanos will report Q1 2026 results before the market opens on May 5, 2026, with analysts forecasting $0.14 EPS and $170.0 million in revenue and the company guiding FY2026 EPS of $0.90–$1.10.
• In the prior quarter (Feb. 24) Avanos beat estimates with $0.29 EPS and $180.9 million revenue, but still showed a negative net margin (-10.4%); analysts expect about $1.00 EPS for the current and next fiscal year.
• The stock trades near its 12‑month high (~$24.75) with a market cap of about $1.15 billion, very high institutional ownership (≈95%), and a current consensus rating of "Reduce".

Avanos Medical (NYSE:AVNS - Get Free Report) is expected to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Avanos Medical to post earnings of $0.14 per share and revenue of $170.00 million for the quarter. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 9:00 AM ET.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.05. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The firm had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.70 million. During the same quarter in the previous year, the business earned $0.43 EPS. The company's revenue was up .7% compared to the same quarter last year. On average, analysts expect Avanos Medical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avanos Medical Price Performance

Shares of NYSE AVNS opened at $24.63 on Tuesday. Avanos Medical has a twelve month low of $9.30 and a twelve month high of $24.75. The stock's 50 day moving average price is $16.09 and its 200-day moving average price is $13.44. The company has a market capitalization of $1.15 billion, a PE ratio of -15.59 and a beta of 1.05. The company has a quick ratio of 1.26, a current ratio of 2.15 and a debt-to-equity ratio of 0.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVNS. Millennium Management LLC grew its position in Avanos Medical by 312.4% in the third quarter. Millennium Management LLC now owns 896,242 shares of the company's stock worth $10,361,000 after acquiring an additional 678,898 shares in the last quarter. Armistice Capital LLC boosted its position in Avanos Medical by 22.8% during the third quarter. Armistice Capital LLC now owns 2,500,000 shares of the company's stock valued at $28,900,000 after buying an additional 464,000 shares during the period. Ameriprise Financial Inc. boosted its position in Avanos Medical by 356.6% during the third quarter. Ameriprise Financial Inc. now owns 591,181 shares of the company's stock valued at $6,834,000 after buying an additional 461,706 shares during the period. Citadel Advisors LLC boosted its position in Avanos Medical by 212.0% during the third quarter. Citadel Advisors LLC now owns 574,104 shares of the company's stock valued at $6,637,000 after buying an additional 390,082 shares during the period. Finally, AQR Capital Management LLC boosted its position in Avanos Medical by 190.4% during the second quarter. AQR Capital Management LLC now owns 560,052 shares of the company's stock valued at $6,855,000 after buying an additional 367,188 shares during the period. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Wall Street Zen cut shares of Avanos Medical from a "buy" rating to a "hold" rating in a report on Saturday, April 18th. Weiss Ratings raised shares of Avanos Medical from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, April 22nd. Finally, Zacks Research raised shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a report on Monday, January 26th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce".

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.